Emerging medical therapies for pulmonary arterial hypertension
Authors:
- Nazzareno GalièNGNazzareno Galiè
- Alessandra ManesAMAlessandra Manes
- Angelo BranziABAngelo Branzi
- 1 November 2002
- journal article
- review article
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 45 (3) , 213-224
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial HypertensionChest, 2002
- Effects of the oral endothelin receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertensionJACC, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Endothelins and Endothelin Receptor AntagonistsCirculation, 2000
- Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertensionHeart, 2000
- Protective Effect of Beraprost Sodium, a Stable Prostacyclin Analogue, in Development of Monocrotaline-Induced Pulmonary HypertensionJournal of Cardiovascular Pharmacology, 1996
- 704-2 Comparative Relation of Neurohormonal Activation to Hemodynamics in Primary or Precapillary Secondary Pulmonary HypertensionJACC, 1995
- Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failureThe American Journal of Cardiology, 1995
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976